Survival for patients with diffuse large B-cell lymphoma varies from person to person and is primarily related to the stage of the lymphoma, the patient’s underlying health, and whether or not aggressive and effective treatment has been administered. Diffuse large B-cell lymphoma is one of the more common types of non-Hodgkin’s lymphoma, accounting for about 40% or more of all non-Hodgkin’s lymphomas. In general, most patients can be cured and survive long-term if they have good underlying health and are treated aggressively in the early to mid stages of the disease. If the patient’s disease progresses more rapidly and is not sensitive to treatment measures such as chemotherapy, the prognosis is poorer and the life expectancy usually does not exceed five years. However, such patients can still improve their quality of life through active treatment. Therefore, patients with diffuse large B-cell lymphoma should be treated aggressively at the early stage of the disease to help prolong survival. In addition, it is also crucial to have regular follow-ups as prescribed by the doctor in order to detect tumor recurrence and treat it in time.